Skip to content
Screener

Tango Therapeutics TNGX Common stock, par value (in dollars per share)

Common stock, par value (in dollars per share) at other companies

Amgen logo
AmgenAMGN
$00.0%
Exelixis logo
ExelixisEXEL
$00.0%

Other financials

Income statement

See full
Revenue--100%
Operating income-$48.8M-14.7%
Net income-$45.5M-14.1%
EPS (diluted)-$0.32+11.1%

Balance sheet

See full
Cash & equivalents$160.0M+162%
Total debt$32.8M-11.3%
Total equity$391.5M+135%
Total assets$435.8M+58.9%

Cash flow

See full
Operating cash flow-$44.4M-6.4%
CapEx-$2.0K-104%
Free cash flow-$44.4M-6.3%

Valuation

See full
Market cap$4.51B+532%
Enterprise value$4.38B+520%
P/S79.1×+49.7×

Profitability

See full
Operating margin-206.2%-61.0pp
Net margin-188.2%-55.4pp
FCF margin-250.1%-49.4pp

Returns & leverage

See full
Return on equity-38.4%-10.5pp
Debt / equity0.1×-0.1×
Current ratio27.4×+21.1×

Where this comes from

Reported directly by Tango Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.

The source filing: Tango Therapeutics’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-221656
Line itemMarch 31, 2026December 31, 2025
Commitments and contingencies (Note 7)
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively
Stockholders' equity:
Common stock, $0.001 par value; 400,000,000 and 200,000,000 shares authorized at March 31, 2026 and December 31, 2025, respectively; 144,162,543 and 135,940,454 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively144136
Additional paid-in capital1,040,143948,971
Accumulated other comprehensive (loss) income(115)224
Accumulated deficit(648,666)(603,152)
Total stockholders’ equity391,506346,179

Item 1. Financial Statements.

FAQ

What is Tango Therapeutics's common stock, par value (in dollars per share)?
Tango Therapeutics (TNGX) reported common stock, par value (in dollars per share) of $0 in Q1 2026.
How has Tango Therapeutics's common stock, par value (in dollars per share) changed year-over-year?
Tango Therapeutics's common stock, par value (in dollars per share) decreased by 0.0% year-over-year, from $0 to $0.
What is the long-term trend for Tango Therapeutics's common stock, par value (in dollars per share)?
Over 5 years (2020 to 2025), Tango Therapeutics's common stock, par value (in dollars per share) has grown at a 0.0% compound annual growth rate (CAGR), from $0 to $0.

Ask your AI about Tango Therapeutics's common stock, par value (in dollars per share).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude